Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

about

Cancer treatment-related cardiac toxicity: prevention, assessment and management.Non-invasive imaging and monitoring cardiotoxicity of cancer therapeutic drugs.Echocardiographic Assessment of Cardiotoxic Effects of Cancer Therapy.

P2860

Q30276456-E6325EAD-4FDE-4DB1-8E59-9E1B3C73486B Q30427656-B350106E-D7B9-4D1D-BCEB-56CDF0374EA4 Q38938410-B9497E20-D4A2-4504-9F93-FAEE69128D89

P2860

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

Item

http://www.wikidata.org/entity/Q50687140

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

2010年學術文章

@zh-hant

name

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

@en

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

@nl

type

Item

label

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

@en

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

@nl

prefLabel

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

@en

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

@nl

P1476

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

@en

P2093

Arzu Kalayci

http://www.w3.org/2001/XMLSchema#string

Can Yucel Karabay

http://www.w3.org/2001/XMLSchema#string

Gonenc Kocabay

http://www.w3.org/2001/XMLSchema#string

Halil Tanboga

http://www.w3.org/2001/XMLSchema#string

Regaip Zehir

http://www.w3.org/2001/XMLSchema#string

P2860

Cardiac dysfunction in the trastuzumab clinical trials experience

Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials.

Trastuzumab-associated cardiotoxicity.

Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management.

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer.

Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review and expert recommendations.

Requirement for neuregulin receptor erbB2 in neural and cardiac development.

The importance of papillary muscle dyssynchrony in predicting the severity of functional mitral regurgitation in patients with non-ischaemic dilated cardiomyopathy: a two-dimensional speckle-tracking echocardiography study.

Subclinical anthracycline- and trastuzumab-induced cardiotoxicity in the long-term follow-up of asymptomatic breast cancer survivors: a speckle tracking echocardiographic study.

P304

296-300

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000323834

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

117

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21358201

http://www.w3.org/2001/XMLSchema#string

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

about

P2860

P2860

Mitral regurgitation due to papillary muscle dyssynchrony during trastuzumab treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698